NCI-2023-09577

An open-label, multi-center phase I/Ib dose finding and expansion study of HRO761 as single agent and in combinations in patients with Microsatellite Instability-High or Mismatch Repair Deficient advanced solid tumors

In a Phase 1/1b study researchers are testing a new treatment called HRO761,for patients with advanced solid tumors that have a condition called Microsatellite Instability-High (MSI-H) or are Mismatch Repair Deficient (dMMR).  The purpose of the study is to find the right dose of HRO761, both when used alone and in combination with other treatments, and to see how well it works in patients with these specific types of tumors.

Microsatellite Instability-High (MSI-H): indicates a high level of DNA errors due to faulty repair mechanisms

Mismatch Repair Deficient (dMMR): signifies ineffective correction of errors during DNA replication, both of which are associated with certain cancers.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05838768

Clinical Trial Site: Columbia

To see all available clinical trials click here.